☰ Accessibility
Market-View-Feature-Image

View on market: Volatility persists, eagerly searching for growth:

Asian markets rose on Friday as news of an upcoming meeting between Donald Trump and Xi Jinping helped ease worries about the trade war. Most regional markets traded higher, led by gains in technology shares, while oil prices fell before the release of US inflation data. Investor sentiment improved after reports that both the US and China plan to support their tech sectors, boosting confidence in the region. The announcement of the leaders’ meeting raised hopes for calmer trade relations. In the US, stocks ended steady after strong performance from technology shares such as Intel, which lifted overall market mood. Treasury yields increased slightly as investors awaited the delayed US inflation report, expected to show steady price growth. Despite some caution over valuations, optimism remains strong as investors continue to buy on market dips. Indian markets also ended slightly higher on Thursday, reflecting the broadly positive global sentiment.

Key Quarterly Results for Today:

ABSLAMC, BAMPSL, BRIGHOTEL, CHTR, CIGNITITEC, COFORGE, DRREDDY, ECLERX, GROARC, INRADIA, ITCHOTELS, JKIPL, JUPITERIN, LATENTVIEW, MIVENMACH, MOSCHIP, NDLVENTURE, PONNIERODE, SBICARD, SBILIFE, SHANTIGEAR, SIGACHI, SPLPETRO, VAKRANGEE.

Economic Calendar:

  • USD: Core PPI (Sep) on 24th October 2025.
  • IND: S&P Global Services PMI (Oct) on 24th October 2025.
  • USD: S&P Global Manufacturing PMI (Oct) on 24th October 2025.
  • IND: S&P Global Manufacturing PMI (Oct) on 24th October 2025.

IPO Watch:

Company Open Close Price (Rs/-) View
NA

Brokerage Radar:

NUVAMA ON CIPLA:

Target Rs 1725 Earlier Target Rs 1651 Recommendation Hold, Eli Lilly deal: A weighty growth affair, India market lucrative, evolving rapidly; Mounjaro sales a testament, What’s in it for Cipla? FY26 revenue boost, head start in semaglutide.

MORGAN STANLEY ON BHARAT FORGE:

Target Rs 1050 Recommendation Equal-weight, Defence Ramping Up, US tariff headwinds key to track, Media reports suggest that India’s army has signed a contract with Bharat Forge, Total order size of Rs 2770 cr.

KOTAK SECURITIES ON LAURUS LABS:

Target Rs 625 Recommendation Sell, A positive, albeit not the perfect, outcome, ARV lumpiness and higher commercial CDMO mix drive 19% operating beat, CDMO on firm footing; investments in differentiated platforms augur well, Valuations remain untenable.

CITI ON HUL:

Target Rs 3000 Earlier Target Rs 2900 Recommendation Buy, Strategic Vision Underpins Medium-term Growth Outlook, Quarterly growth was adversely impacted by transitory trade destocking in anticipation of the GST rate cuts, Mgmt. estimates 200 bps impact to growth.

International Markets:

U.S & Europe:

Particulars     23rd  Oct   Chg. Chg.(%)
Nasdaq 22,941.80 201.40 0.89
Dow 46,734.61 144.20 0.31
FTSE 9,578.57 63.57 0.66
CAC 8,225.78 18.91 0.23
DAX 24,207.79 56.66 0.23
Dow Fut.* 46,773.70 39.09 0.08

*As per 24th October.

Asian markets:

Particulars   24th  Oct Chg. Chg.(%)
GIFT Nifty                  26,001.00 24.10 0.09
Nikkei 49,327.00 685.39 1.39
Straits Times 4,426.55 10.28 0.23
Hang Seng 26,111.00 143.02 0.55
Shanghai                        3,932.46 10.05 0.26

Stocks strong on Chart:

Index F&O Cash
SBIN HDFCAMC RALLIS INDIA
HDFC BANK FEDERALBNK CEAT
ICICI BANK DABUR BEML
TCS PFC MAX ESTATE
RIL ICICIGI NIPPON AMC
INFY RECLTD MINDACORP

Commodities & Currency:

Particulars Current Price Chg.(%)
USD/INR 87.764 0.01
Brent 65.56 -0.65
Gold 124,247 0.12
Silver 148,660 2.13

FIIs & DIIs:

Particulars       23rd Oct        21st Oct
FIIs                          -1,165.94 96.72
DIIs 3,893.73 -607.01

News Updates:

Cipla: It enters into an agreement with Eli Lilly to distribute Tirzepatide in India under the brand name Yurpeak. The drug is used to treat Type-2 diabetes and obesity and will be priced the same as Eli Lilly’s Mounjaro.
Syrma SGS: It enters into an agreement with Premier Energies to acquire KSolare Energy for Rs 170 crore.
Hero MotoCorp: It expands into the UK market through a partnership with MotoGB. In addition the company has launched Euro 5+ range led by Hunk 440, expanding its global presence to 51 countries.
Vodafone Idea: It invests Rs 26,000 as the first tranche out of the total proposed investment of Rs 1.56 crore in the capital of ABRen SPV 3.
Kaynes Technology: The company’s subsidiary enters into an agreement with Frauscher Sensor Technology Group GmbH to acquire a 7% stake in Sensonic GmbH for 1 Euro.
Insolation Energy: It to migrate its listing from BSE SME to BSE and NSE main boards. The board has approved borrowing limit up to Rs 5,000 crore.
Syngene International: It confirms news on expansion of its Biologics facility with new ADC bioconjugation capability, stating the investment is part of its ordinary business.
Source: Moneycontrol, Bloomberg Quint, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 214 

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Vindhyachal Prasad, Elite Wealth Limited, vindhyachal@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

  • all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
  • No part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale. Legal Entities Disclosures

Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

  1. Reports
  2. a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
  • EWL or its associates or relatives, have no actual/beneficial ownership of one %. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
  • EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
          1. Compensation
    • EWL or its associates have not received any compensation from the subject company in the past twelve months;
    • EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
  • EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
  • EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
  • EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research
  1. In respect of Public Appearances
  • EWL or its associates have not received any compensation from the subject company in the past twelve months;
  • The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL